Enliven Therapeutics, Inc. Income Statement
ELVN / Health Care|6 years of annual SEC 10-K data (FY2019-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| SG&A Expense | $23.8M | $19.0M | $7.8M | $13.0M | $9.5M | $5.1M |
| R&D Expense | $80.8M | $64.6M | $31.0M | $38.4M | $32.2M | $19.0M |
| Operating Income | -$104.6M | -$83.5M | -$38.8M | -$51.4M | -$41.7M | -$24.1M |
| Income Tax | $232.0K | $0 | $0 | - | - | - |
| Net Income | -$89.0M | -$71.6M | -$37.7M | -$51.4M | -$41.4M | -$23.5M |
| EPS (Basic) | -$1.89 | -$2.01 | -$12.05 | -$2.37 | - | - |
| EPS (Diluted) | -$1.89 | -$2.01 | -$12.05 | -$2.37 | - | - |
| Shares Outstanding | 47.1M | 35.5M | 3.1M | 21.7M | 13.9M | 702.5K |